MetLife Investment Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $610K | Hold |
43,629
| – | – | ﹤0.01% | 1590 |
|
|
2025
Q1 | $588K | Sell |
43,629
-666
| -2% | -$8.98K | ﹤0.01% | 1641 |
|
|
2024
Q4 | $849K | Buy |
44,295
+7,914
| +22% | +$152K | ﹤0.01% | 1504 |
|
|
2024
Q3 | $828K | Hold |
36,381
| – | – | ﹤0.01% | 1497 |
|
|
2024
Q2 | $473K | Buy |
36,381
+10,811
| +42% | +$141K | ﹤0.01% | 1743 |
|
|
2024
Q1 | $448K | Buy |
25,570
+3,299
| +15% | +$57.8K | ﹤0.01% | 1736 |
|
|
2023
Q4 | $485K | Hold |
22,271
| – | – | ﹤0.01% | 1701 |
|
|
2023
Q3 | $342K | Hold |
22,271
| – | – | ﹤0.01% | 1859 |
|
|
2023
Q2 | $530K | Buy |
22,271
+2,428
| +12% | +$57.8K | ﹤0.01% | 1660 |
|
|
2023
Q1 | $505K | Hold |
19,843
| – | – | ﹤0.01% | 1637 |
|
|
2022
Q4 | $580K | Buy |
19,843
+6,129
| +45% | +$179K | ﹤0.01% | 1545 |
|
|
2022
Q3 | $281K | Hold |
13,714
| – | – | ﹤0.01% | 2070 |
|
|
2022
Q2 | $159K | Buy |
+13,714
| New | +$159K | ﹤0.01% | 2458 |
|